-+ 0.00%
-+ 0.00%
-+ 0.00%

Pyxis Oncology Announces Robust Preclinical Data Supporting Unique Extracellular Linker Payload Cleaving Mechanism Of Action Of Micvotabart Pelidotin And Validating MICVO's Ongoing Clinical Development

Benzinga·04/25/2025 17:20:38
Listen to the news

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders

Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism

Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone

Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's unique, three-pronged mechanism of action of driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death, further reinforcing the potential patient benefit for MICVO as a monotherapy and in combination with an anti-PD-1 therapy

BOSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, announced today robust preclinical data supporting the unique extracellular linker payload cleaving mechanism of action of micvotabart pelidotin (MICVO, formerly referred to as PYX-201) and validating MICVO's ongoing clinical development. MICVO is a first-in-concept antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. This is a compelling target for cancer therapeutics as the physiological expression of EDB+FN is very low in healthy adult tissues while found to be highly expressed in a variety of solid tumor tissues. Data will be presented in two poster sessions on Monday, April 28 from 2:00 PM to 5:00 PM CT at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois.